Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition.

ABSTRACT:

Purpose

The objective of this study was to evaluate adverse events (AEs) in patients who received both immune checkpoint inhibitors and thoracic radiation therapy (RT). In particular, we compared the rate of toxicities of concurrent versus sequential delivery of thoracic RT and checkpoint inhibitors.

Methods and materials

Patient and treatment characteristics were collected on all patients at our institution who were treated with programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and/or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors and underwent thoracic RT (n = 79). Receiving both treatments within 1 month was considered concurrent (n = 35; 44%), and any treatment up to 6 months apart was considered sequential (n = 44; 56%). The pri

SUBMITTER: von Reibnitz D 

PROVIDER: S-EPMC6128092 | biostudies-literature | 2018 Jul-Sep

REPOSITORIES: biostudies-literature